Navigation Links
Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement
Date:8/10/2009

he replay.

About KYNAPID

KYNAPID (vernakalant hydrochloride) Injection, or vernakalant (iv), is an investigational new drug for the rapid conversion of acute atrial fibrillation to sinus rhythm. Its mechanism of action involves the selective blockade of multiple ion channels in the heart that are known to be active during episodes of atrial fibrillation.

In October 2003, Cardiome granted Astellas Pharma US, Inc. an exclusive license to develop and commercialize KYNAPID in North America, with Astellas responsible for 75% of development costs. Astellas and Cardiome conducted four successful Phase 3 clinical trials which demonstrated the potential for KYNAPID as a conversion agent. In December 2004 and September 2005, we announced positive top-line results for the first and second pivotal Phase 3 atrial fibrillation trials, or ACT 1 and ACT 3, respectively. In addition, positive top-line results from ACT 2, evaluating KYNAPID for the treatment of atrial fibrillation following cardiac surgery, were announced in June 2007. Astellas also conducted an open-label safety study, or ACT 4, in order to gather additional safety data.

The NDA for KYNAPID was submitted in December 2006. In December 2007, the FDA Cardiovascular and Renal Drugs Advisory Committee recommended to the FDA that KYNAPID be approved for rapid conversion of acute atrial fibrillation to sinus rhythm. In August 2008, Astellas received an Approvable letter from the FDA.

About Cardiome

Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ National Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

About Astellas


'/>"/>
SOURCE Cardiome Pharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. aTyr Pharma Raises an Additional $12 Million
2. Texas Kidney Community: CMS Authorization to Survey 22 New Dialysis Centers Excellent First Step Toward Opening Additional Pending Facilities, Creating More Local Jobs
3. SETO Holdings, Inc. Enters Into Two Additional Leases for Two New Hearing Centers in Maryland and Virginia
4. Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol
5. For Treatment of Type 2 Diabetes, 89 Percent of Surveyed Endocrinologists Identify a Need for Additional GLP-1 Analogues and 71 Percent Say the Same About DPP-IV Inhibitors
6. Specialty Hospitals of Washington Adds Additional Skilled Nursing Facility Beds at United Medical Center in South East DC
7. King Provides Additional Information on the REMOXY(R) NDA Resubmission Plan
8. Visit to the doctor: The supply of additional private services is increasing
9. Business, Health Care Leaders Call on Texas Employers to Cover Smoking Cessation Benefits for an Additional 100,000 People by 2010
10. Mylan Receives FDA Approval for Additional Strength of Generic Restoril(R)
11. New Jersey University Hospital to Pay Additional $2 Million to Resolve Fraud Claims That Facility Double Billed Medicaid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) – ... the current treatment landscape, unmet needs, current pipeline ... Stivarga is a drug which is used in ... Ingelheim is developing nintedanib (BIBF-1120), an orally available ... in the US, Europe, and Japan. The drug ...
(Date:12/25/2014)... Dylan Queen, a famous online company supplying women’s special ... prom dresses, most of which are priced under $200. ... the promotion is valid until Jan. 22, 2015; the ... market. , The prom dresses in this new collection ... strapless, empire strapless chiffon, one shoulder, floor-length, V-neck beading, ...
(Date:12/25/2014)... FL (PRWEB) December 25, 2014 When head ... find themselves in a frenzy to get rid of it ... But families in Coral Gables now have the solution right ... second salon clinic location, Lice Troopers provides full spectrum head ... the Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut ...
(Date:12/25/2014)... -- Among early stage breast cancer patients who undergo ... percent will eventually develop leukemia as a result of ... comes from a review of more than 20,000 breast ... suggests that the risk for developing treatment-related leukemia, though ... "The frequency of bone marrow cancers such as ...
(Date:12/25/2014)... 25, 2014 Plugin creators from Pixel ... A fully customizable business presentation tool made specifically for ... ProFire 5k business tool, users can now display their ... of Pixel Film Studios. “ProFire 5k gives users a ... add professionalism to a presentation” , Pixel Film Studios ...
Breaking Medicine News(10 mins):Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... of biology in the School of Science at Indiana ... eye and vision research organization in the world for ... blindness caused by macular degeneration, retinitis pigmentosa and other ... Research in Vision and Ophthalmology (ARVO) will present Meyer ...
... researchers have shown for the first time how peppermint ... to 20% of the population. In a paper ... , researchers from the University,s Nerve-Gut Research Laboratory explain ... soothing inflammatory pain in the gastrointestinal tract. Dr ...
... shows how inflammation can help cause cancer. Chronic inflammation ... inflammatory bowel disease is associated with up to 25 ... the Ohio State University Comprehensive Cancer Center Arthur ... Institute (OSUCCC James) found that inflammation stimulates a ...
... more effective than cutting calories for individuals who want to ... UT Southwestern Medical Center researchers. "What this study tells ... to reduce the amount of fat in your liver, you ... assistant professor of internal medicine at UT Southwestern and the ...
... , MONDAY, April 18 (HealthDay News) -- Patients with do-not-resuscitate ... after surgery, even after non-emergency procedures, a new study finds. ... used to revive someone who is clinically unresponsive and lacks ... and in the August print issue of the journal ...
... , MONDAY, April 18 (HealthDay News) -- Infection ... of many college students -- and little exposure to sunlight ... sclerosis, a new study suggests. "MS is more common ... lead researcher, Dr. George C. Ebers, of the University of ...
Cached Medicine News:Health News:IUPUI faculty member to receive national innovative vision research award 2Health News:Peppermint earns respect in mainstream medicine 2Health News:Study shows how inflammation can lead to cancer 2Health News:Limiting carbs, not calories, reduces liver fat faster, UT Southwestern researchers find 2Health News:People With DNR Orders More Apt to Die After Any Surgery 2Health News:Can Common Virus, Lack of Sunlight Boost MS Risk? 2
(Date:12/24/2014)... LONDON , December 24, 2014 /PRNewswire/ ... expected to grow at an average rate of 8.1%. ... and volume. Hip, knee and spine surgeries are the ... emerging economies they have a lower penetration. Increased number ... use of composites. Non-metallic orthopedic devices have gained popularity ...
(Date:12/24/2014)... Dec. 23, 2014  Advanced Medical Isotope Corporation ... primarily in the development of brachytherapy devices and ... announced that it has filed a de ... Administration ("FDA") for marketing clearance for its patented ... the U.S. Food, Drug and Cosmetic Act (the ...
(Date:12/24/2014)... , Dec. 23, 2014   Synageva BioPharma ... biopharmaceutical company developing therapeutic products for rare disorders, ... (EMA) of the Marketing Authorization Application (MAA) for ... granted the company,s request for accelerated assessment, which ... review time.   The MAA, and ...
Breaking Medicine Technology:Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... , GREENVILLE, S.C. , ... provide an online, real-time webcast and rebroadcast of its conference ... for the first quarter of fiscal 2010, which will be released ... The live broadcast of Span-America,s conference call will be available ...
... , , ... ERES ), a leading provider of centralized services to the ... ERT Knowledge Series of educational papers, written by ERT experts. ... trials today and further establishes ERT as an experienced and ...
Cached Medicine Technology:Span-America Announces First Quarter Conference Call On The Internet 2ERT Demonstrates Patient Safety Expertise in Clinical Trials with New Knowledge Series of Papers 2ERT Demonstrates Patient Safety Expertise in Clinical Trials with New Knowledge Series of Papers 3ERT Demonstrates Patient Safety Expertise in Clinical Trials with New Knowledge Series of Papers 4ERT Demonstrates Patient Safety Expertise in Clinical Trials with New Knowledge Series of Papers 5
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: